Business
Sitryx appoints Adam Mostafa as Chief Financial Officer
Sitryx appoints Adam Mostafa as Chief Financial Officer Adam joins Sitryx with deep expertise in biotechnology capital markets, M&A and business development and strategic leadership Oxford, UK and Boston, MA – 8 September 2025 – Sitryx Therapeutics (“the Company”), a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in autoimmune and inflammatory disease, today announces the appointment of Adam Mostafa as Chief Financial Officer (CFO), effective t
About this update from X4 Pharmaceuticals, Inc.
[{"type":"image","alt":"Sitryx Therapeutics","displaySize":"","headline":null,"caption":"Sitryx Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":107,"url":"https://media.zenfs.com/en/globenewswire.com/cb76f0259938047b73c2c78baef758b7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/cA5tRJuenoRnFe1jiRpV_A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/cb76f0259938047b73c2c78baef758b7","width":300,"height":107}},"lazy":false},{"type":"text","content":"Sitryx appoints Adam Mostafa as Chief Financial Officer ","length":55,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Adam joins Sitryx with deep expertise in biotechnology capital markets, M&A and business development and strategic leadership","length":129,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":129,"olType":false},{"type":"text","content":"Oxford, UK and Boston, MA – 8 September 2025 – Sitryx Therapeutics (“the Company”), a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in autoimmune and inflammatory disease, today announces the appointment of Adam Mostafa as Chief Financial Officer (CFO), effective today.","length":323,"tagName":"p"},{"type":"text","content":"With over 25 years of experience, Adam is a seasoned biotech executive and financial leader. He joins Sitryx with a distinguished background spanning across biotech and healthcare financial sectors, where he has raised over $1 billion in institutional capital and secured multiple strategic partnerships, while helping to lead companies from early-stage clinical efforts to approval and commercialization. Most recently, Adam served as CFO for X4 Pharmaceuticals (Nasdaq: XFOR), where he played a pivotal role in driving the company’s financial and growth strategies, including the close of X4’s reverse merger with Arsanis in 2019 and subsequent Nasdaq public listing, and the FDA approval and commercial launch of XOLREMDI®, a novel rare disease therapeutic. Prior to this, he held the role of CFO at Abpro Holdings (Nasdaq: ABP). He currently sits on the Board of Satellos Bioscience (TSX: MSCL) and Precision Biologics and is a Senior Advisor to Cumberland Pharmaceuticals (Nasdaq: CPIX).","length":992,"tagName":"p"},{"type":"text","content":"Adam’s earlier car...